三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
EGFRex20ins突变局部晚期或转移性NSCLC治疗路径
EGFRex20ins突变局部晚期或转移性NSCLC治疗路径
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:223KB
图片尺寸:1712*830
同报告图片
/
4
5oqx5q2J77yM5oiR5peg5rOV5o+Q5Y+W5Zu+54mH5Lit55qE5pWw5o2u5oiW55Sf5oiQ6KGo5qC844CC6K+35oKo5o+Q5L6b5paH5a2X5o+P6L+w5oiW5YW25LuW5L+h5oGv77yM5oiR5Lya5bC95Yqb5biu5Yqp5oKo44CC
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
所属报告:
迪哲医药-公司研究报告:专注小分子原始创新差异化管线厚积薄发-241215(36页).pdf
打包全文图表
相关数据
ADC联合IO单抗治疗一线NSCLC全球三期研究启动时间
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
收藏
行业数据
2026-07-14
原图定位
查看详情
KRASG12C一线治疗NSCLC竞争格局(截至2026-6-25)
收藏
竞争格局
2026-07-01
原图定位
查看详情
全球KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
中国KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
SHR-A2009用于EGFR突变型NSCLC的1期临床研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
SHR-A2009用于一线NSCLC患者的研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
表A.14 法国的风险转移规则(全国性AYII)
收藏
行业数据
2026-04-01
原图定位
查看详情
PD(L)1*VEGF双抗单药针对一线NSCLC数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
各药物针对IO耐药NSCLC临床数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
驱动基因阴性晚期NSCLC治疗格局
收藏
竞争格局
2026-02-24
原图定位
查看详情
NSCLC1L全球竞争格局AK112BNT327707
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
收藏
竞争格局
2026-01-28
原图定位
查看详情
HER2+不可切除局部晚期/转移性胃/胃食管结合部癌治疗格局
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
收藏
竞争格局
2025-12-31
原图定位
查看详情
SI-B001针对PD-(L1)抑制剂治疗失败的野生型NSCLC的mPFS数据
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
收藏
行业数据
2025-12-26
原图定位
查看详情
图表4国NSCLC驱动基因谱
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
收藏
行业数据
2025-12-03
原图定位
查看详情
图表20EGFR耐药后NSCLC试验数据比
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
收藏
行业数据
2025-12-03
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
Exon 20ins突变NSCLC一线治疗缺乏靶向疗法,舒沃替尼为后线治疗唯一I级推荐用药。根据EGFR 20外显子插入突变非小细胞肺癌规范化诊疗中国专家共识(2024版),目前国内尚无一线治疗局部晚期或转移性EGFR ex20ins突变NSCLC识别风险,发现价值 请务必阅读末页的免责声明 靶向药物获批,参考无驱动基因晚期NSCLC的一线治疗方案。埃万妥单抗(A mivantamab) 联合化疗已获FDA批准一线治疗局部晚期或转移性EGFR ex20ins NSCLC,国内尚未获批。对于无法耐受或拒绝化疗或体力状况(PS)评分较差等患者,一线可选择舒沃替尼。舒沃替尼也是后线治疗唯一优先推荐药物。莫博赛替尼是全球首款上市的用于治疗含铂化疗期间或之后进展且携带EGFR ex20ins突变的局部晚期或转移性NSCLC成人患者的靶向药物,于2021年获得FDA加速审批,2023年1月获NMPA加速审批上市。但根据武田2023.10.2官网公告,武田已经主动撤回莫博赛替尼在美国上市,因为III期确证性研究未达到主要研究终点(来源:武田官网)。
行业数据
原图定位
当前图表所属:
迪哲医药-公司研究报告:专注小分子原始创新差异化管线厚积薄发-241215(36页).pdf
全球已上市BTK抑制剂
全球在研肿瘤相关JAK抑制剂
DCF估值
盈利预测核心假设
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》